The independent French consulting and engineering group Oteis has entered into a deal with Total Energies to acquire the firm’s sustainable consultancy and solutions affiliate Greenflex. This move is in line with Total Energies’ long-term strategy of focusing its activities on energy production and supply.

Abbvie has recently announced a 195-million-dollar investment in its North Chicago, Illinois manufacturing plant. The move aims to expand domestic active pharmaceutical ingredient production in the U.S.

Total Energies, Equinor, and Shell have recently announced that they have transported by vessel the first CO2 volumes from Heidelberg Materials’ cement factory in Brevik, Norway to Northern Lights’ CO2 storage project in Øygarden, Norway.

Today Artificial Intelligence has entered every industry and the pharma sector is no different. Major pharma companies are actively making use of AI to accelerate drug discovery and carry out efficient clinical trials. However, integrating this technology into GxP-compliant pharma production still remains a complex challenge.

Under a long-term agreement signed between Nouryon and Arauco, Nouryon will supply sodium chlorate and chlorine dioxide solutions for Arauco’s new 4.6-billion-dollar pulp mill in Mato Grosso do Sul, Brazil.

Merck has received this certification for Pharmaceutical Auxiliary Materials and it is claimed to be the first company in the industry to receive this certification. Excipact is a widely recognized standard for the manufacturing of non-sterile excipients.

Schubert has expanded its ‘4You Service’ portfolio and now offers its customers measurable benefits in terms of efficiency, availability and sustainability – both in analogue and digital form.

Evonik has recently launched its new world-scale alkoxides production facility in Singapore. With this project, the company intends to strengthen its ability to meet rising demand for alkoxides across Asia.

Idemitsu Kosan has begun commercial operations of its new black pellet plant in Vietnam. With an annual production capacity of 120,000 tons, the project is the country’s first commercial scale BP production facility.

Roche’s US subsidiary Genentech has broken ground on a new manufacturing facility in Holly Springs, North Carolina. The 700-million-dollar project is expected to support the production of the company’s future portfolio of metabolic medicines, including next-generation treatments for obesity.